You are here: Industry Insights > RedHill Biopharma

News List

Opaganib COVID-19 Study Passes Second Independent Committee Review americanpharmaceuticalreview
October 14, 2020
RedHill Biopharma announced the U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia has passed its second pre-scheduled safety review by the independent Safety Monitoring Committee (SMC) with a ...
RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2 americanpharmaceuticalreview
September 24, 2020
RedHill Biopharma announced opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue.
RedHill Biopharma Announces Positive Recommendation from COVID-19 Study americanpharmaceuticalreview
August 31, 2020
RedHill Biopharma announced its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in patients hospitalized with severe COVID-19 pneumonia, has successfully passed the first scheduled independent Safety Monitoring Committee (SMC) review.
RedHill Biopharma partners with NIAID for potential Covid-19 drug pharmaceutical-technology
April 22, 2020
Israel-based RedHill Biopharma has partnered with the US National Institute of Allergy and Infectious Diseases (NIAID) to study its RHB-107 (upamostat, WX-671) drug candidate in non-clinical tests for the treatment of Covid-19.
IND submitted for opaganib, potential COVID-19 treatment europeanpharmaceuticalreview
April 21, 2020
RedHill Biopharma has submitted its Investigational New Drug application for its drug opaganib, for the treatment of COVID-19, to the FDA.
AstraZeneca Announces Divestment of Movantik to RedHill Biopharma Complete americanpharmaceuticalreview
April 07, 2020
AstraZeneca has completed the previously communicated agreement to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill).
AZ licences Movantik rights to RedHill pharmatimes
April 02, 2020
AstraZeneca has completed its deal to sublicense global rights to Movantik (naloxegol), (excluding Europe, Canada and Israel) to RedHill Biopharma.
RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III b3cnewswire
August 01, 2017
RedHill Biopharma Ltd. reported that it has received a unanimous positive recommendation from the DSMB to continue the study as planned.
RedHill Biopharma announces continuation of Phase III Study with RHB-104 for Crohn’s Disease pharmaasia
August 01, 2017
The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study.
RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D b3cnewswire
July 18, 2017
RedHill Biopharma Ltd. announced that the last patient enrolled in the Phase II study with BEKINDA® (RHB-102)(1) 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) has completed the treatment course and follow-up visit.

Previous page 1 2 3 Next page